New Federal Privacy Standards for Substance Use Treatment Records

New federal privacy standards for substance use disorder (SUD) treatment records will take effect by early 2026, requiring compliance from SUD providers, health plans, clinicians, health information exchanges (HIEs), and vendors. The final rule under 42 CFR Part 2 introduces significant changes that organizations must address to avoid enforcement and penalties similar to those outlined in the Health Insurance Portability and Accountability Act (HIPAA).

In a recent discussion, attorneys from Epstein Becker Green, including Lisa Pierce Reisz, David Shillcutt, and Laura DePonio, joined Nichole Sweeney, General Counsel and Chief Privacy Officer at CRISP, to analyze the implications of this final rule. They emphasized how the new standards align with HIPAA, while also highlighting the unique aspects of the privacy regulations specifically designed for SUD treatment records.

Key Changes and Compliance Challenges

One of the primary changes introduced by the final rule is the adoption of HIPAA’s enforcement and penalty structure for violations. This shift means that organizations can expect similar repercussions for non-compliance as they would under HIPAA, underscoring the importance of adhering to the new regulations.

The attorneys identified operational readiness as the main challenge for organizations rather than technological upgrades. Many may find that adjusting internal processes and training staff will be more complex than implementing new technology solutions. As the healthcare landscape continues to evolve, the need for organizations to ensure they are operationally prepared is paramount.

Additionally, payors and HIEs will face expanded compliance duties, leading to a significant shift in how data access is managed. This change places a greater responsibility on these entities to understand their obligations under the new rules and implement necessary adjustments to their operations.

The Importance of Patient Consent

Patient consent remains a central tenet of the 42 CFR Part 2 final rule. The emphasis on consent highlights the need for organizations to prioritize privacy and ensure that patients are fully informed about how their information will be used and shared. The group discussed how this focus on consent is crucial in maintaining trust between healthcare providers and patients, particularly in the sensitive context of substance use treatment.

The attorneys also cautioned that many organizations may overlook specific aspects of the new regulations, which could lead to compliance risks. They encouraged healthcare entities to thoroughly review the final rule and seek legal guidance to navigate the complexities of the updated privacy standards.

In conclusion, the 42 CFR Part 2 final rule signifies a major shift in the landscape of privacy regulations surrounding substance use disorder treatment. As organizations prepare for these changes, it is essential to address the operational challenges and ensure that patient consent remains at the forefront of their compliance efforts. Understanding and adapting to these new requirements will not only help mitigate risks but also foster a more secure environment for patient care.